Neuren Pharmaceuticals Limited (ASX: NEU)

Market Cap	2.69B
Revenue (ttm)	231.93M
Net Income (ttm)	157.08M
Shares Out	127.27M
EPS (ttm)	1.20
PE Ratio	17.58
Forward PE	38.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,032
Open	21.74
Previous Close	21.80
Day's Range	21.03 - 21.78
52-Week Range	10.02 - 25.95
Beta	2.01
Analysts	n/a
Price Target	26.64 (+26.32%)
Earnings Date	Jul 29, 2024

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2023, NEU's revenue was 231.93 million, an increase of 1493.66% compared to the previous year's 14.55 million. Earnings were 157.08 million, an increase of 85270.11%.